The translation of biological data on neuro- protection from animals to human ICH patients may face the same difficulties encountered by the ischemic stroke neuroprotection field, such as identifying the correct animal model system and a clinically relevant time frame for treat- Emerging methods such as prehospital administra- tion of candidate neuroprotectants327 should increase the range of feasible treatment approaches and time windows for acute ICH. As targeted treatments for acute ICH continue to be ana- lyzed, it is important to note that many of the gains seen in Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/ Advisory Board Other J. Claude Hemphill III University of California, San Francisco NIH/NINDS* None None None None None None Steven M. Greenberg Massachusetts General Hospital Avid Radiopharmaceuticals ; NIH ; NINDS ; None None None None None None Craig S. Anderson The George Institute for Global Health, University of Sydney; Royal Prince Alfred Hospital The National Health and Medical Research (NHMRC) of Australia None Takeda China*; Covidien*; Bayer* None None Pfizer*; The Medicines Company* None Kyra Becker University of Washington School of Medicine NINDS None None None None None None Bernard R. Bendok Northwestern Medical Faculty Foundation NIH None None None None None None Mary Cushman University of Vermont NIH/NHLBI ; NIH/NINDS None None None None None None Gordon L Fung University of California San Francisco Medical Center None None None None None None None Joshua N. Goldstein Massachusetts General Hospital CSL Behring ; NIH*; NINDS None None None None CSL Behring* None R. Loch Macdonald Independent Medical Practitioner Brain Aneurysm Foundation*; Canadian Institutes of Health Research*; Heart and Stroke Foundation of Canada*; Physicians Services Incorporated Foundation* None None None Edge Therapeutics* Actelion Pharmaceuticals* None Pamela H. Mitchell University of Washington NIH None None None None None None Phillip A. Scott University of Michigan NIH/NINDS None None None None None None Magdy H. Selim Harvard Medical Faculty Physicians NIH/NINDS None None None None Daiichi-Sankyo* None Daniel Woo University of Cincinnati NINDS None None None None None None This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. 